Breaking News, Financial News

Financial Report: Biogen

SPINRAZA drives growth in the quarter with sales up 73%

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen
3Q Revenues: $3.4 billion (+12%)
3Q Earnings: $1.4 billion (+18%)
YTD Revenues: $9.9 billion (+11%)
YTD Earnings: $3.5 billion (+24%)
Comments: Multiple sclerosis (MS) revenues were relatively flat at $2.3 billion in the quarter, including approximately $137 million in royalties on the sales of OCREVUS (+112%). TECFIDERA sales were $1.1 billion, up 2% in the quarter. Avonex sales were down 10% to $482 million. TYSABRI sales were flat at $470 million. Revenue growth was driven in part by SPINRAZA, which contributed $468 million in global revenues, up 73%.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters